Skip to main content
Clinical Trials/KCT0007169
KCT0007169
Recruiting
未知

Total neoadjuvant therapy with short-course radiotherapy versus long-course neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Seoul National University Hospital0 sites348 target enrollmentTBD
ConditionsNeoplasms

Overview

Phase
未知
Intervention
Not specified
Conditions
Neoplasms
Sponsor
Seoul National University Hospital
Enrollment
348
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • (1\) Histologically diagnosed locally advanced rectal cancer (stage II/III)
  • (2\) The distal border of the tumor located \=10 cm from the anal verge
  • (3\) Men and women aged 19\-80 years
  • (4\) No evidence of distant metastasis (including paraaortic LN, common \& external iliac LN) on abdominal pelvic CT or chest CT scan
  • (5\) ECOG performance \=1 and be capable of activities for daily living
  • (6\) American Society of Anesthesiologists (ASA) Physical Status Classification System Class I\~II
  • (7\) No history of any other systemic treatment (chemotherapy, immunotherapy) or radiotherapy for rectal cancer
  • (8\) No history of intrapelvic radiotherapy
  • (9\)The following investigation criteria should be satisfied:
  • Bone marrow function: absolute neutrophils \=1,500/mm3, platelets \=75,000/mm3

Exclusion Criteria

  • (1\) Histological carcinoma other than rectal adenocarcinoma or adenocarcinoma arising from inflammatory bowel disease
  • (2\) Suspected distant metastasis
  • (3\) NCI CTC grade 1 or higher peripheral neuropathy
  • (4\) Uncontrolled or severe cardiovascular disease, myocardial infarction within 6 months, NYHA grade 3 or higher heart failure, or uncontrolled angina
  • (5\) Infection or other disease that is not currently controlled
  • (6\) History of other malignancies within 5 years (except for cured superficial skin cancer or cervical carcinoma in situ)
  • (7\) History of organ transplant requiring immunosuppressive therapy
  • (8\) Uncontrolled epilepsy or psychosis
  • (9\) Pregnant or lactating women, women of childbearing potential who do not intend to actively use contraception, or men who are planning pregnancy or do not intend to actively use contraception
  • (10\) Cases required to continue concomitant treatment expected to interact with oxaliplatin, such as flucytosine, phenytoin, or warfarin

Outcomes

Primary Outcomes

Not specified

Similar Trials